With these first results, targeting CD9 in AML seems to be an interesting approach to eliminate LSCs and prevent relapses with monoclonal antibodies or even chimeric antigen receptor (CAR) T‐cell therapy. The gene discussed is CD9; the disease is acute myeloid leukemia.